Abpro Holdings, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
Abpro Holdings, a preclinical biotechnology company, filed an S-1/A to register shares for resale under a $50 million equity purchase agreement, while facing substantial doubt about its ability to continue as a going concern and multiple Nasdaq delisting notices.
Abpro Holdings, a biotechnology company, filed an S-1 registration statement for a $50 million standby equity purchase agreement, while facing substantial doubt about its ability to continue as a going concern.
Abpro Holdings, a biotechnology company, has received multiple Nasdaq delisting notices and faces substantial doubt about its ability to continue as a going concern, reporting a net loss of $3.887 million in Q1 2025 and an accumulated deficit of $120 million.
Abpro Holdings is seeking to raise up to $50 million by reselling common stock through a Standby Equity Purchase Agreement with YA II PN, Ltd.
S-1/A: Abpro Holdings Files for Potential $370 Million Offering, Including Warrant Shares and Resales
Abpro Holdings seeks to register the issuance of warrant shares and the resale of common stock and warrants by selling securityholders, potentially amounting to a $370 million offering.
Abpro Holdings, Inc. has filed a registration statement for the resale of up to 31.8 million shares of common stock and 13.9 million warrants by existing securityholders, along with the primary issuance of up to 28.9 million shares upon warrant exercise.